$145.04
-11.03-7.07%
Últ. Act.: Oct 26, 7:09 AM
Axsome Therapeutics (AXSM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Axsome Therapeutics (AXSM) publicó su última previsión de enero 4, 2024 para fiscal year 2023. La compañía estimó ingresos en un rango de $204M - $204M para el período.
En comparación con la previsión anterior, Axsome Therapeutics elevado redujo su previsión de ingresos desde un rango anterior de $71M - $71M.
Axsome Therapeutics ha emitido 2 actualizaciones de orientación entre el enero 4, 2024 y el enero 4, 2024. During this period, the company raised its outlook 1 time, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.87 | $-0.83 | $-0.72 | $-0.87 |
| Actual | $-0.99 | $-1.26 | $-0.56 | $-0.68 |
| Surprise | -13.8% | -51.8% | +22.2% | +21.8% |
| Revenue | ||||
| Estimate | $222.3M | $190.3M | $193.2M | $163.4M |
| Actual | $218.4M | $191.2M | $196.0M | $171.0M |
| Surprise | -1.77% | +0.48% | +1.47% | +4.64% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.64 | $-0.15 | $-0.21 | $0.33 |
| Revenue | ||||
| Consensus | $250.0M | $292.2M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 10, 2026 | $-0.99 | $-0.87 | -13.8 % |
| Q1 | May 4, 2026 | $-1.26 | $-0.83 | -51.8 % |
| Q4 | Feb 23, 2026 | $-0.56 | $-0.72 | 22.2 % |
| Q3 | Nov 3, 2025 | $-0.68 | $-0.87 | 21.8 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 10, 2026 | $218.40M | $222.33M | -1.77 % |
| Q1 | May 4, 2026 | $191.20M | $190.28M | 0.48 % |
| Q4 | Feb 23, 2026 | $196.00M | $193.16M | 1.47 % |
| Q3 | Nov 3, 2025 | $170.99M | $163.41M | 4.64 % |